Perfosfamide
Perfosfamide is a small molecule pharmaceutical. Perfosfamide was first approved as Hc #1 on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alveora hemorrhoid master | C200263 | 2025-02-20 |
| blue goo nerve ease pain relief | C200263 | 2025-09-10 |
| cyhot cream with lidocaine | OTC monograph not final | 2018-02-20 |
| dch nerve pain relief roll-on | C200263 | 2024-12-19 |
| dch pain relief | C200263 | 2024-12-19 |
| dch pain relief roll-on | C200263 | 2024-12-19 |
| dermfree hemorrhoid | C200263 | 2024-08-15 |
| equate pain relief cream | C200263 | 2023-12-19 |
| fluconazole 4% / ibuprofen 2% / itraconazole 1% / terbinafine hcl 4% | unapproved drug other | 2019-04-24 |
| healmusz hemorrhoid fissure | C200263 | 2025-09-25 |
Show 26 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight loss | D015431 | — | — | — | — | — | 1 | 2 | 3 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | 1 | — | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | 6 | 4 | — | — | 10 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | 3 | 2 | — | — | 5 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | 2 | — | — | 4 |
| Leukemia | D007938 | — | C95 | 1 | — | 2 | — | — | 3 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | — | 2 | 1 | — | — | 3 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | — | 1 | 3 | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | 1 | 3 | 1 | — | — | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | 1 | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | 1 | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | 1 | — | — | 2 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | 1 | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | — | 2 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | 1 | 2 | — | — | — | 2 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 1 | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 1 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | 1 | 1 | — | — | — | 1 |
| Myc genes | D016259 | — | — | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | 3 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 2 | 3 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | 1 | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | 1 | 2 |
| Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 5 | 5 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 4 | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 4 | 4 |
| Sclerosis | D012598 | — | — | — | — | — | — | 4 | 4 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 4 | 4 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 3 | 3 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | — | — | 3 | 3 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 3 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 3 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 3 | 3 |
Show 100 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Perfosfamide |
| INN | perfosfamide |
| Description | 4-hydroperoxycyclophosphamide is a phosphorodiamide that is the active metabolite of the nitrogen mustard cyclophosphamide. It has potent antineoplastic and immunosuppressive properties. It has a role as an antineoplastic agent, an immunosuppressive agent, an alkylating agent, a metabolite and a drug allergen. It is a phosphorodiamide, a nitrogen mustard, a peroxol and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; isophosphoramide mustard derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=P1(N(CCCl)CCCl)NC(OO)CCO1 |
Identifiers
| PDB | — |
| CAS-ID | 39800-16-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL61511 |
| ChEBI ID | 196991 |
| PubChem CID | 38347 |
| DrugBank | — |
| UNII ID | U880A4FUDA (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use